For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
KEY FINDINGS
The Asia Pacific pharmaceutical continuous manufacturing market is anticipated to grow at a CAGR of 9.72% over the forecast period of 2020-2028. A surge in the number of pharmaceutical companies and the rising demand for continuous manufacturing systems is propelling the market growth.
MARKET INSIGHTS
The high growth rate of the Asia Pacific pharmaceutical continuous manufacturing market is further researched by dividing the region into Thailand, Vietnam, India, Japan, South Korea, Indonesia, Australia & New Zealand, China, and the rest of Asia Pacific that includes Malaysia, Philippines, and Singapore. In South Korea, R&D-based pharmaceutical companies are continuously striving for productivity and effectiveness to face the challenges of R&D resources. The industry is driven by highly qualified and experienced R&D manpower, a nationwide collaboration between the industry, academic and public research organizations, strong will for new drug development, and a vision for the global market. In 2020, GEA experts analyzed the advantages of continuous manufacturing to understand the scope of its markets in South Korea. In Thailand, the government is pursuing to make the country a leader for pharmaceuticals and medical devices and a world-class provider of medical care. Thailand is likely to establish a continuous manufacturing process to manufacture pharmaceutical products in a faster and efficient manner.
In countries like Indonesia, the pharmaceutical industry is expected to grow between 12%-13% per annum. Indonesia is home to 30,000 out of the 40,000 medicinal plants known globally. These factors will create demand for pharmaceutical continuous manufacturing. In Vietnam, Sanofi has plans to build a new manufacturing plant, its largest investment to produce pharmaceuticals and healthcare products. The demand from various pharmaceutical industries is driving the market. In the rest of the Asia Pacific region, the growing geriatric population and their dependence on pharmaceutical products are augmenting the market growth.
COMPETITIVE INSIGHTS
Hosokawa Micron Corporation, GEA Group, L.B. Bohle, Pfizer Inc, Eli Lilly, and Company, etc. are some of the prominent companies functioning in the market.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments